Esperion Therapeutics ESPR Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax

Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies

AmgenAMGN

——

Regeneron PharmaceuticalsREGN

——

Nurix Therapeutics, Inc.NRIX

——

BridgeBio PharmaBBIO

——

Nektar TherapeuticsNKTR

——

BioCryst PharmaceuticalsBCRX

——

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?: Esperion Therapeutics (ESPR) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $0 in Q1 2026.